Milestones
October 2021
VPCIR biosciences launches a webshop offering its first commercial product: A human topoisomerase 1 (hTOP1) enzyme for laboratory use available now
July 2021
VPCIR biosciences have obtained European trademark protection for our disruptive VPCIR technology. We expect to launch the first VPCIR™ products in about 6 months time
March 2021
VPCIR has successfully negotiated a €134.000 loan arrangement with the Danish Vaekstfonden
December 2020
The group of dedicated business angels, organized in VPCIR Invest ApS decides to increase their commitment and investment level in VPCIR
May 2020
EU Commission grants Seal of Excellence to VPCIR biosciences Aps
December 2019
Investment by a group of Danish business angels at DKK 1.7 M
December 2018
VPCIR receives a grant of DKK 0.9M from Novo Nordisk Foundation
November 2018
Development of first-generation assay (Listeria) commences
October 2018
VPCIR receives a grant of DKK 1.5M from Innovation Fund Denmark
April 2018
Submission of VPCIR patent application by AU/CUHK
February 2018
Establishment of VPCIR biosciences ApS
September 2017
Proof of concept in testing for E. coli using restriction enzyme patterns
2010 - 2017
Basic research Aarhus University (AU), Aarhus University Hospital and Chinese University of Hong Kong (CUHK) on restriction enzymes